Literature DB >> 21159715

Prevalence of autoantibodies related to some autoimmune disorders in patients with chronic idiopathic thrombocytopenic purpura.

Cengiz Demir1, Ramazan Esen, Murat Atmaca, Servet Efe.   

Abstract

We investigated the prevalence of antinuclear antibody (ANA), thyroid antimicrosomal (AMA) and antithyroglobulin (ATA), antigliadin (AGA) immunoglobulin G (IgG)-A, anti-endomisium (EMA) IgG-A, and tissue transglutaminase (tTG) IgG-A in 87 patients with chronic idiopathic thrombocytopenic purpura (cITP) and in 95 healthy controls. Antinuclear antibody positivity was found in 13 of 87 patients and 3 of 95 controls (P = .007). Antithyroglobulin positivity was found in 27 of patients and in 7 of the controls (P < .001). AMA positivity was found in 20 of patients and 8 of the controls (P = 0.008). Antigliadin IgG was positive in 17 patients and 1 controls (P < .001) whereas Antigliadin IgA was positive in 9 of patients and in 1 of the controls (P = .007). Anti-endomisium (IgG and IgA were not different between both groups. Tissue transglutaminase IgG was detected in 7 of patients and in 1 of the controls (P = .029). Tissue transglutaminase IgA was detected in 5 of patients and in none of the controls (P = .023). We believe that larger studies are needed to determine the long-term impact and clinical importance of these autoantibodies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21159715     DOI: 10.1177/1076029610387588

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  5 in total

1.  Markers of autoimmunity in immune thrombocytopenia: prevalence and prognostic significance.

Authors:  Marie A Hollenhorst; Hanny Al-Samkari; David J Kuter
Journal:  Blood Adv       Date:  2019-11-26

2.  Standardized clinical assessment and management plans (SCAMPs): perspectives on a new method to understand treatment decisions and outcomes in immune thrombocytopenia.

Authors:  Rachael F Grace
Journal:  Semin Hematol       Date:  2013-01       Impact factor: 3.851

3.  ANA-positive primary immune thrombocytopaenia: a different clinical entity with increased risk of connective tissue diseases.

Authors:  Yuan Liu; Shiju Chen; Guomei Yang; Bin Wang; Jinying Lan; Fan Dai; Peishi Rao; Puqi Wu; Hongyan Qian; Guixiu Shi
Journal:  Lupus Sci Med       Date:  2021-10

Review 4.  The Role of Hydroxychloroquine as a Steroid-sparing Agent in the Treatment of Immune Thrombocytopenia: A Review of the Literature.

Authors:  Fatemeh Mohammadpour; Mona Kargar; Molouk Hadjibabaie
Journal:  J Res Pharm Pract       Date:  2018 Jan-Mar

5.  Could Antinuclear Antibody Positivity Be a Factor Affecting Treatment Response in Immune Thrombocytopenia Patients on Eltrombopag?

Authors:  Mehmet Baysal; Volkan Baş; Elif Ümit; Hakkı Onur Kırkızlar; Ahmet Muzaffer Demir
Journal:  Turk J Haematol       Date:  2021-06-24       Impact factor: 1.831

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.